Javascript must be enabled to continue!
Abstract 1562: Proteomic analysis of citrullinated targets regulated by the p53-PADI4 pathway
View through CrossRef
Abstract
We recently reported that p53 regulates protein citrullination through the transcriptional regulation of PADI4 that converts an arginine residue in proteins to a citrulline residue. In response to DNA damage, p53-PADI4 pathway induces citrullination of NPM1, Histone H4, and Lamin C, and subsequently promotes apoptotic pathway. To verify the clinical significance of PADI4 in human carcinogenesis, we screened the mutation of PADI4 in hepatocellular carcinoma and found three non-synonymous mutations among 104 cancer tissues (2.9%). Then we evaluated these three mutations as well as 8 somatic mutations reported by ICGC or COMP projects. We found that 8 among 11 mutations remarkably inhibited the enzymatic activity of PADI4 protein. To identify novel PADI4 substrates, we conducted proteome analysis using HEK293T cells ectopically transfected with wild type or mutant PADI4 expressing plasmid. Among more than 10000 peptides identified by the liquid chromatography MS/MS analysis, 265 peptides (2.2%) were citrullinated in PADI4-introduced cells, while less than 0.4% of total peptides were citrullinated in control or mock transfected cells. Pathway analysis revealed that RNA binding proteins such as hnRNPs are dominantly citrullinated by PADI4, indicating that possible role of protein citrullination in RNA processing.
Citation Format: Chizu Tanikawa, Koji Ueda, Hidewaki Nakagawa, Yusuke Nakamura, Koichi Matsuda. Proteomic analysis of citrullinated targets regulated by the p53-PADI4 pathway. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1562. doi:10.1158/1538-7445.AM2014-1562
American Association for Cancer Research (AACR)
Title: Abstract 1562: Proteomic analysis of citrullinated targets regulated by the p53-PADI4 pathway
Description:
Abstract
We recently reported that p53 regulates protein citrullination through the transcriptional regulation of PADI4 that converts an arginine residue in proteins to a citrulline residue.
In response to DNA damage, p53-PADI4 pathway induces citrullination of NPM1, Histone H4, and Lamin C, and subsequently promotes apoptotic pathway.
To verify the clinical significance of PADI4 in human carcinogenesis, we screened the mutation of PADI4 in hepatocellular carcinoma and found three non-synonymous mutations among 104 cancer tissues (2.
9%).
Then we evaluated these three mutations as well as 8 somatic mutations reported by ICGC or COMP projects.
We found that 8 among 11 mutations remarkably inhibited the enzymatic activity of PADI4 protein.
To identify novel PADI4 substrates, we conducted proteome analysis using HEK293T cells ectopically transfected with wild type or mutant PADI4 expressing plasmid.
Among more than 10000 peptides identified by the liquid chromatography MS/MS analysis, 265 peptides (2.
2%) were citrullinated in PADI4-introduced cells, while less than 0.
4% of total peptides were citrullinated in control or mock transfected cells.
Pathway analysis revealed that RNA binding proteins such as hnRNPs are dominantly citrullinated by PADI4, indicating that possible role of protein citrullination in RNA processing.
Citation Format: Chizu Tanikawa, Koji Ueda, Hidewaki Nakagawa, Yusuke Nakamura, Koichi Matsuda.
Proteomic analysis of citrullinated targets regulated by the p53-PADI4 pathway.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1562.
doi:10.
1158/1538-7445.
AM2014-1562.
Related Results
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
The Complex Interplay Between p53 and Aneuploidy in Cancer
The Complex Interplay Between p53 and Aneuploidy in Cancer
In this thesis, we dived into the complex relationship between p53 and aneuploidy. p53 acts as a central tumor suppressor that responds to diverse cellular stresses, including DNA ...
Abstract 1262: Depletion of dominant-negative mutant p53 improves the efficacy of mutant p53 reactivators.
Abstract 1262: Depletion of dominant-negative mutant p53 improves the efficacy of mutant p53 reactivators.
Abstract
TP53 (p53) forms a tetramer and functions as a transcription factor to upregulate mRNA expression of genes involved in cell cycle progression and apoptos...

